Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

IMP4927

Small molecule · developed by Impact Therapeutics

Phase 3 Most advanced trial

IBO Developer

1 Registered trials

What is IMP4927?

IMP4927 is an investigational small-molecule drug studied in Ovarian Cancer.

At a glance

Drug type: Small molecule
Therapy area: Oncology
Developer: Impact Therapeutics, Inc. (IBO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04169997	Phase 3	Ovarian Cancer	Active not recruiting	IBO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ovarian Cancer

More from Impact Therapeutics

IMP9064 Investigational Potrasertib Investigational Senaparib Investigational

Sources

ClinicalTrials.gov NCT04169997

Updated Oct 3, 2026. Something wrong or missing? Report it on the IBO page.

Follow IBO, the company behind IMP4927

See IBO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IBO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z